Dupilumab Asthma Sleep Study (MORPHEO)

  • STATUS
    Recruiting
  • End date
    Jul 18, 2023
  • participants needed
    260
  • sponsor
    Sanofi
Updated on 24 May 2022
corticosteroids
pulmonary function test
nitric oxide
bronchodilator
forced expiratory volume
fractional exhaled nitric oxide
eosinophil count

Summary

Primary Objective:

To assess the effect of dupilumab on sleep

Secondary Objectives:

  • To evaluate the effect of dupilumab on additional patient reported sleep outcomes
  • To evaluate the effect of dupilumab on objective sleep assessment
  • To evaluate the effect of dupilumab on asthma symptoms
  • To evaluate the effect of dupilumab on lung function
  • To evaluate the safety of dupilumab

Description

Study duration per participant will be approximately 16 weeks and up to 29 weeks including up to 5 weeks screening period, a 12-week treatment period and up to 12 weeks post-treatment follow-up period

Details
Condition Asthma
Treatment Placebo, SAR231893
Clinical Study IdentifierNCT04502862
SponsorSanofi
Last Modified on24 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Physician diagnosis of asthma based on the Global Initiative for Asthma (GINA) 2020 Guidelines for ≥12 months treated with medium to high dose inhaled corticosteroid (ICS) and a second controller (ie, long-acting beta agonist, leukotriene receptor antagonist). A third controller is allowed but not mandatory. The dose regimen should be stable for at least 1 month before the study and during the screening period
History of at least one asthma exacerbation within 1 year prior to screening. Exacerbation is defined as deterioration of asthma that results in emergency treatment, hospitalization due to asthma, or treatment with systemic steroids (oral or injectable)
Eosinophils ≥150 cells/μL and fractional exhaled nitric oxide (FeNO) ≥25 ppb during screening, prior to randomization
NOTES
Historical values of blood eosinophil count meeting the eligibility criterion measured within 6 months prior to screening Visit 1 in the absence of oral corticosteroid (OCS) treatment are allowed
FeNO value to be checked for eligibility at Visit 2 as well
Asthma control questionnaire (ACQ)-5 ≥2.5 at screening Visit 1 and Visit 2, prior to
randomization
Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) ≤ 80% of predicted normal during screening, prior to randomization
Exhibit bronchodilator reversibility (≥12% and 200 mL improvement in FEV1 post short-acting beta agonist administration) during screening period, prior to randomization, unless reversibility test meeting the inclusion criteria was done within 6 months prior to screening Visit 1
Weekly average nocturnal awakenings due to asthma symptoms in the week prior to screening Visit 1 is ≥1

Exclusion Criteria

Current smoker
Former smoker for 10 years with a smoking history of >10 pack-years
Asthma exacerbation during screening, prior to randomization
History or clinical evidence of chronic obstructive pulmonary disease (COPD) including Asthma-COPD Overlap Syndrome (ACOS) or any other significant lung disease (eg, lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, bronchiectasis, Churg-Strauss Syndrome)
History of or current evidence of clinically significant non-respiratory diseases that in the opinion of the investigator may interfere with the aims of the study or put the participant at undue risk
Active tuberculosis (TB) or non-tuberculous mycobacterial infection, or a history of incompletely treated TB will be excluded unless it is well documented by a specialist that the participant has been adequately treated and can now start treatment with a biologic agent, in the medical judgment of the Investigator and/or infectious disease specialist. Tuberculosis testing would be performed on a country by country basis, according to local guidelines if required by Regulatory Authorities or ethics boards
Diagnosed active endoparasitic infection; suspected or high risk of endoparasitic infection, unless clinical and (if necessary) laboratory assessment have ruled out active infection before randomization
History of human immunodeficiency (HIV) infection or positive HIV test at screening Visit 1
Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiprotozoals, or antifungals within 2 weeks before screening
Known or suspected immunodeficiency including history of invasive opportunistic infections, despite infection resolution
Current evidence of clinically significant oncological disease
History of systemic hypersensitivity or anaphylaxis to any biologic therapy
Severe uncontrolled depression
Sleep disturbances not related to asthma, including sleep apnea, hypersomnia, or insomnia secondary to chronic pain, atopic dermatitis (AD), COPD or other conditions
Participant who works night shift (ie, any work between 8 pm and 6 am)
Erratic sleep habits, as determined by the Investigator
Restless leg syndrome or periodic limb movement disorder
Chronic treatment with oral corticosteroid (OCS) for more than 2 weeks before screening Visit 1
Participant taking sedative, anxiolytic, or hypnotic treatments, including melatonin, within 3 months before randomization
Participant taking systemic sedative antihistamines (excluding newer generations of antihistamines) or theophylline
Current treatment with antidepressants, lipophilic beta blockers, clonidine, opioids, or other medications known to interfere with sleep and may confound the study assessments, as determined by the Investigator
Treatment with live (attenuated) vaccine within 4 weeks before screening Visit 1
Participant who has taken biologic therapy (including dupilumab)/systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc) within 2 months or 5 half-lives before screening Visit 1, whichever is longer
NOTE: For participants who have vaccination with live, attenuated vaccines planned during the course of the study (based on national vaccination schedule/local guidelines), it will be determined, after consultation with a physician, whether the administration of vaccine can be postponed until after the end of the study, (i.e. after the 12 week follow-up period off-treatment or until the participant switches to commercialized dupilumab or other biologic product, whichever comes first), or preponed to before the start of the study without compromising the health of the participant
Participant for whom administration of live (attenuated) vaccine can be safely postponed would be eligible to enroll into the study
Participant who have their vaccination preponed can enroll in the study only after a gap of 4 weeks following administration of the vaccine
The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note